Cowen initiated coverage on shares of Exagen (NYSE:XGN) in a research report sent to investors on Monday morning, The Fly reports. The firm issued an outperform rating and a $17.00 price objective on the stock.
Shares of XGN opened at $13.00 on Monday. Exagen has a fifty-two week low of $11.54 and a fifty-two week high of $19.50.
In other Exagen news, major shareholder Bio-Exagen L.P. H.I.G. bought 425,000 shares of the firm’s stock in a transaction dated Monday, September 23rd. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,950,000.00.
Exagen Inc operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome, and scleroderma, as well as other disorders, including fibromyalgia.
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.